Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

Inclusion Criteria:

• The participant has given written informed consent to participate.

• The participant is 18 years of age or older at the Screening Visit.

• The participant has a diagnosis of osteoarthritis of the knee based on AmericanCollege of Rheumatology criteria and functional capacity class of I to III.

• There is a documented history indicating that participant has insufficient painrelief with previous Standard of Care.

Exclusion Criteria:

• The participant has past joint replacement surgery of the index knee.

• The participant has a history of significant trauma or surgery (e.g., open orarthroscopic) to the index knee within 12 months of Screening.

• The participant has periarticular pain at the index knee from any cause other thanosteoarthritis, including referred pain, bursitis, tendonitis.

• The participant has clinical hip osteoarthritis on the side of the index knee.

• The participant has a history of osteonecrosis, subchondral insufficiency fracture,atrophic osteoarthritis, rapidly progressing osteoarthritis (RPOA) Type I or TypeII,pathologic fracture, primary or metastatic tumor, or joint infection in the indexknee.

• The participant has significant malalignment of anatomical axis (medial angle formedby the femur and tibia) of the target knee (varus >10°, valgus >10°) by radiographas assessed by independent Central Readers at Screening Visit.

• The participant has other conditions that could affect trial endpoint assessments ofthe index knee.

• The participant has current clinically significant disease(s) or condition(s) thatmay affect safety assessments, or any other reason which may preclude theparticipant's participation for the full duration of the trial.

• The participant has a history of hypersensitivity to resiniferatoxin (RTX) or anysimilar component (capsaicin, chili peppers).

• The participant is currently participating or was participating in anotherinvestigational drug trial within 3 months prior to the Screening Visit.

• The participant is an employee of the investigator or trial site, with directinvolvement in the proposed trial or other trials under the direction of thatinvestigator or trial site or is a family member of the employees or theinvestigator.

The non-index knee is not eligible for treatment in the trial, if any of the knee-related exclusion criteria applies to the non-index knee.